Moraga, Calif. October 15, 2015—Trigemina, Inc., a biopharmaceutical company focused on the discovery and development of targeted neurological drug therapies, announced today that Charles Yeomans, the company’s president and chief executive officer, will present at the BIO 14th Annual BIO Investor Forum in San Francisco next week. The presentation will be webcast and will occur on Tuesday, October 20, 2015 at 3:15 p.m. PDT.
To access the live and subsequently archived webcast of the presentation, please click on the following link: http://trigemina.com/events/. Please connect to the website at least 15 minutes prior to the presentation to allow for any software download that may be necessary.
Trigemina (pronounced Tri-jem’-in-uh) is a privately owned, clinical stage company focused on the discovery and development of highly targeted neurological drug therapies. Trigemina’s lead product candidate, TI-001, is a clinical stage, patented new drug candidate that includes oxytocin. TI-001 has shown promising results for use as a safe and effective therapy for most forms of chronic or subacute head pain, and is currently in development for the prevention of high frequency migraine. Further information is available on the Company’s website, trigemina.com.
President and CEO, Trigemina
Cook Williams Communications, Inc.